Items Tagged ‘Zykadia’

June 9th, 2017

FDA Expands use of Zykadia® in First-Line ALK-Positive Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) approved the expanded use of Zykadia® (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose cancers are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. About Zykadia Zykadia is an oral, selective inhibitor of ALK, a gene that can fuse […]

View full entry

Tags: ALK-Positive Non-Small Cell Lung Cancer, ceritinib, Lung Cancer, News, precision medicine, Zykadia


November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc